Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJOncoAlert Journal Club | TRUST: radical upfront surgical therapy in advanced ovarian cancer

Christina Fotopoulou • 8 Aug 2025
VJOncoAlert Journal Club
Gynecological Cancer Ovarian Cancer
TRUST

In the latest episode of the VJOncoAlert Journal Club, Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the timing of surgery in advanced ovarian cancer. Despite high tumor loads, optimal or maximized effort surgery resulted in similar overall survival rates among patients. However, progression-free survival was significantly better in the primary debulking arm.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christina Fotopoulou

TRUST: optimal timing of surgical therapy in advanced ovarian cancer
2:00
TRUST: optimal timing of surgical therapy in advanced ovarian cancer
Christina Fotopoulou • 25 Jun 2025
Hurdles to providing equitable surgical care for ovarian cancer
2:10
Hurdles to providing equitable surgical care for ovarian cancer
Christina Fotopoulou • 25 Jun 2025
When should clinicians perform surgery after NAC in ovarian cancer?
3:33
When should clinicians perform surgery after NAC in ovarian cancer?
Christina Fotopoulou • 25 Jun 2025
Is a role for surgery in stage IV ovarian cancer?
3:26
Is a role for surgery in stage IV ovarian cancer?
Christina Fotopoulou • 26 Jun 2024

Related Videos

Selective PARP1 inhibitors show promise in ovarian and breast cancer
1:13
Selective PARP1 inhibitors show promise in ovarian and breast cancer
Martin Hojgaard • 29 May 2026
EIK1003-001: Phase I/II trial of EIK1003 in PROC and HER- breast cancer
0:55
EIK1003-001: Phase I/II trial of EIK1003 in PROC and HER- breast cancer
Martin Hojgaard • 29 May 2026
BLUESTAR: puxitatug samrotecan safety & efficacy in endometrial or ovarian cancer
1:28
BLUESTAR: puxitatug samrotecan safety & efficacy in endometrial or ovarian cancer
Linda Mileshkin • 30 May 2026
The future targeted therapies and ADCs in metastatic endometrial cancer
3:46
The future targeted therapies and ADCs in metastatic endometrial cancer
Ka Yu Tse • 17 Dec 2025
The content of VJOncology is intended for healthcare professionals